| Clinical Applications of Immunotoxins Softcover Repri Edition Contributor(s): Frankel, Arthur E. (Editor) |
|
 |
ISBN: 3642721559 ISBN-13: 9783642721557 Publisher: Springer OUR PRICE: $104.49 Product Type: Paperback Published: December 2011 |
| Additional Information |
| BISAC Categories: - Medical | Hematology - Medical | Immunology - Medical | Oncology - General |
| Dewey: 614.599 |
| Series: Current Topics in Microbiology and Immmunology |
| Physical Information: 0.3" H x 6.14" W x 9.21" (0.45 lbs) 122 pages |
| Descriptions, Reviews, Etc. |
| Publisher Description: 1 2 D. FITZGERALDI, I. PASTAN, and J. ROBERTUS Introduction . . . . . . . . . . . . . I 2 Toxin Structure-Function Properties 2 2. 1 Functions. . . . . . . . . . . . . . . . . . . . . . . . 2 2. 2 Binding. . . . . . . . . . . . . . . . . . . . . . . . . 3 3 Intracellular Processing - Cleavage and Reduction . . . . . . 4 3. 1 Cytosolic Activity . . . . . . . . . . . . . . . . 5 4 Immunotoxin Design and Testing. 6 5 Conclusion. . 8 References. . . . . 8 1 Introduction While various treatment approaches for cancer include reversal of the transformed phenotype, stimulation of immune responses, inhibition of metastatic spread and deprivation of key nutrients, the goal of immunotoxin treatment is the direct killing of malignant cells. Because they are enzymatic proteins that act catalytically to kill cells, bacterial and plant toxins are often employed as the cell-killing component of immunotoxins. Here we provide background information into the structure-func- tion relationships of toxins and discuss how they can be combined with cell-binding antibodies or other ligands to generate immunotoxins. Bacterial and plant toxins (e. g., diphtheria toxin, Pseudomonas exotoxin and ricin) are among the most toxic substances known. However, because they bind to cell surface receptors that are present on most normal cells, unmodified toxins are generally useless as anti-cancer agents. To convert toxins into more selective agents, their binding domains are either eliminated or disabled and replaceq with cell- binding antibodies that are tumor-selective. |